Healthy adults
Conditions
Interventions
Placebo group: 10 capsules taken once daily with water or lukewarm water after breakfast.
Test supplement group: 10 capsules taken once daily with water or lukewarm water after breakfast.
Sponsors
IMEQRD Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age: 20 to under 60 years. 2. Gender: Japanese men and women. 3. BMI: Between 25.0 kg/m^2 and 30.0 kg/m^2. 4. Ability to input electronic diaries via smartphone or PC. 5. Individuals who have received a sufficient explanation about the study's objectives and content, fully understand them, voluntarily wish to participate and provide written consent for participation.
Exclusion criteria
Exclusion criteria: 1. Currently undergoing treatment for any disease with medication or herbal remedies (occasional use permitted). 2. Individuals under dietary or exercise therapy supervised by a physician. 3. Individuals with a history or current presence of severe diseases. 4. Individuals with gastrointestinal disorders or a history of gastrointestinal surgery affecting digestion and absorption (appendicitis excluded). 5. Individuals who have undergone obesity surgery within the past year or are scheduled for such surgery. 6. Individuals consuming healthy foods or supplements that may affect obesity, blood sugar, or lipid metabolism (including foods with specific health claims or functional labeling; participation allowed if discontinued after consent). 7. History or presence of drug or food allergies. 8. Individuals with irregular lifestyles due to night shifts or rotating work schedules. 9. Individuals planning significant lifestyle changes (diet, sleep, exercise, etc.) during the study period. 10. Heavy alcohol consumers. 11. Individuals planning overseas travel during the study period. 12. Pregnant, breastfeeding, or planning to become pregnant during the study period. 13. Individuals who have undergone blood collection exceeding 200 mL within the past month or 400 mL within the past three months. 14. Individuals who participated in other clinical studies within the past month or are currently participating/planning to participate during the study period. 15. Individuals with implanted orthopedic metal devices. 16. Individuals considered unsuitable for participation by the principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in body fat mass over 12 weeks, measured using the DXA method. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Change in lean body mass (LBM) over 12 weeks. - Change in body weight and BMI over 12 weeks. - Change in waist circumference over 12 weeks. - Changes in fat mass, fat percentage, and lean body mass in specific regions (arms, legs, trunk, abdomen [Android], and hips [Gynoid]) over 12 weeks, measured using the DXA method. - Changes in blood markers (leptin, adiponectin, T-cho, HDL-C, LDL-C, TG) over 12 weeks. | — |
Countries
Japan
Contacts
Public ContactYoshitada Hira
IMEQRD Co., Ltd. Planning and Sales Department
Outcome results
None listed